Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.08M Buy
9,010
+1,783
+25% +$206K 0.36% 65
2025
Q4
$767K Buy
7,227
+1,276
+21% +$120K 0.25% 83
2025
Q3
$504K Buy
5,951
+63
+1% +$5.19K 0.18% 121
2025
Q2
$471K Buy
5,888
+3,575
+155% +$284K 0.19% 112
2025
Q1
$209K Sell
2,313
-986
-30% -$92.1K 0.11% 167
2024
Q4
$331K Sell
3,299
-1,314
-28% -$135K 0.17% 119
2024
Q3
$527K Sell
4,613
-100
-2% -$11.9K 0.43% 57
2024
Q2
$587K Buy
4,713
+174
+4% +$22.4K 0.38% 55
2024
Q1
$602K Buy
4,539
+407
+10% +$50.2K 0.67% 36
2023
Q4
$454K Buy
+4,132
New +$429K 0.58% 52

Other funds holding MRK

Sunpointe's MRK Position: Q1 2026 in Review

Sunpointe increased its Merck (MRK) stake by 25% in Q1 2026, buying an estimated $206K and bringing the position to 9,010 shares worth $1.08M. The position accounts for 0.36% of the portfolio, ranked #65.

Sunpointe first reported a position in MRK in Q4 2023 and has held it in 10 quarters since. 3,775 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Sunpointe held 9,010 shares of Merck worth $1.08M as of Q1 2026.
  • Sunpointe bought 1,783 Merck shares in Q1 2026, an estimated $206K.
  • Merck made up 0.36% of Sunpointe's portfolio in Q1 2026, its #65 holding.
  • Sunpointe first reported a position in Merck in Q4 2023 and has held it in 10 quarters since.
  • 3,775 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Sunpointe's 13F filing for Q1 2026, filed 21 Apr 2026.